CDTX — Cidara Therapeutics Balance Sheet
0.000.00%
- $272.14m
- $82.89m
- $1.28m
Annual balance sheet for Cidara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 35.9 | 59.7 | 32.7 | 35.8 | 190 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 11.2 | 5.36 | 5.83 | 16.2 | 1.69 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 57.2 | 71.7 | 45.1 | 60.9 | 211 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.21 | 2.54 | 1.32 | 5.13 | 3.96 |
Other Long Term Assets | |||||
Total Assets | 60.4 | 75.3 | 47.5 | 67 | 215 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 38.6 | 34 | 41.4 | 67.4 | 49.6 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 49.7 | 53.8 | 61.9 | 75.2 | 51.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 10.7 | 21.6 | -14.4 | -8.21 | 163 |
Total Liabilities & Shareholders' Equity | 60.4 | 75.3 | 47.5 | 67 | 215 |
Total Common Shares Outstanding |